Gilead (GILD) had its estimates and price target increased by Jefferies (JEF) after the approval of the stribild quad pill, as well as higher pricing announced for the future. A $55 price target was set with a hold rating.
Gilead (GILD) had its estimates and price target increased by Jefferies (JEF) after the approval of the stribild quad pill, as well as higher pricing announced for the future. A $55 price target was set with a hold rating.
